Objective:To determine the relationship between EGFRvⅢ expression and sensitivity of SKOV3 cell to Gefitinib and to give rational guidance to clinical medication. Methods:Plasmid pcDNA4/TO-EGFRvⅢ was stably transfected into SKOV3 cell and the cell strains stably expressing EGFRvⅢ were screened out by zeocin antibiotics and named SKOV3-EGFRvⅢ. MTT was used to assess the viability of SKOV3- EGFRvⅢ cell and SKOV3 cell treated by Gefitinib. Nude mice allograft tumor models bearing SKOV3 and SKOV-EGFRvⅢ were treated by Gefitinib. The sensitivity of the tumor model to Gefitinib was assessed by measuring the tumor size. Results:Results of Western blot indicated that SKOV3-EGFRvⅢ cell strain was successfully established. According to the results of MMT,after being treated by Gefitinib,the mortality was lower in SKOV3-EGFRvⅢ cell than in SKOV3 cell and the inhibi-tion effect of Gefitinib was less intense on tumor model carrying SKOV3-EGFRvⅢ cell than on that carrying SKOV3. Conclusion:Over expression of EGFRvⅢ in ovarian cancer SKOV3 cell results in its decreased sensitivity to Gefitinib.
Reference
Related
Cited by
Get Citation
ZHANG Li, BAO Lewen. Effect of EGFRvⅢ expression on sensitivity of ovarian cancer SKOV3 cell after Gefitinib treatment[J]. Journal of Chongqing Medical University,2012,37(11):940-942